Springer [1,2] The use of statins has become more widespread [] and this trend extends to people over 80 years. JE reports grants from the Medical Research Council and the British Heart Foundation during the conduct of the study, and a grant from Boehringer Ingelheim outside the submitted work. CP reports a grant from Merck, outside the submitted work; and personal fees from Merck, Pfizer, Sanofi, Amgen, and Daiichi-Sankyo, outside the submitted work. the In this review, we present avail- able evidence from randomized clinical trials, as well as relative community and post-approval data directly applicable to the management of CVD in the elderly, in both primary and secondary prevention. BM reports grants from the Medical Research Council, British Heart Foundation, and the National Institute for Health Research Oxford Biomedical Research Centre during the conduct of the study, and grants from Merck outside the submitted work.
Nevertheless, the benefits in outcome offered by statins cannot be neglected. 2016 Sep 1;1(6):708-13. doi: 10.1001/jamacardio.2016.1577.Expert Rev Cardiovasc Ther. All authors contributed to manuscript revisions. AK, JF, BM, and CB had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of data analyses.RO'C, EB, IF, CW, and JS have nothing to disclose. PR reports a research grant from AstraZeneca during the conduct of the study; and research grants from Novartis, Pfizer, and Kowa, outside the submitted work. There is less definitive direct evidence of benefit in the primary prevention setting among patients older than 75 years, but evidence supports the use of statin therapy in older people considered to have a sufficiently high risk of occlusive vascular events.Correspondence to: CTT Secretariat, National Health and Medical Research Council (NHMRC) Clinical Trials Centre, Camperdown, NSW 2050, Australia Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, Oxford OX3 7LF, UK AK, CB, JS, and RC established the collaboration.
AK, JF, BM, CB, RC, and JS devised the study concept. Location of Repository The adverse effects associated with high doses of statins and their interactions with other drugs may give rise to more problems in the elderly population. The current meta-analysis work at the CTC was supported by a programme grant from the Australian National Health and Medical Research Council and a grant from the National Heart Foundation, Australia; and at the CTSU was supported by the UK Medical Research Council, British Heart Foundation, and Cancer Research UK. In this review, we present available evidence from randomized clinical trials, as well as relative community and post-approval data directly applicable to the management of CVD in the elderly, in both primary and secondary prevention. Statin Prescribing in the Elderly: Special Considerations Curr Atheroscler Rep. 2017 Oct 11;19 (11):47. doi ... Our aim was to examine the current evidence behind prescribing statins to individuals over 65 years of age with emphasis on those older than 75. AG reports personal fees from Aegerion Pharmaceuticals, Arisaph Pharmaceuticals, DuPont, Esperion Therapeutics, Kowa, Merck, Roche, Vatera Capital, ISIS Pharmaceuticals, Weill Cornell Medicine, and Amgen, outside the submitted work. The effects of statins in the elderly are better informed by absolute effects and the number needed to evaluate the benefit to harm balance. Such an approach enables patients to make more informative choices.
RC, CB, CR, JE, LB, AK, JS, and EB collected the data. Results of the Cholesterol and Recurrent Events (CARE) trial.MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial.Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis.Statins for primary prevention of cardiovascular disease in elderly patients: systematic review and meta-analysis.Statins for the primary prevention of cardiovascular disease in the elderly.Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis.2016 ESC/EAS guidelines for the management of dyslipidaemias.KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease.Statins in the elderly: a patient-focused approach.Myopathy in older people receiving statin therapy: a systematic review and meta-analysis.Protocol for analyses of adverse event data from randomized controlled trials of statin therapy.Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Statin treatment reduces car- diovascular morbidity and mortality in middle-aged adults. The adverse effects associated with high doses of statins and their interactions with other drugs may give rise to more problems in the elderly population.